诺诚健华(09969.HK)抑制剂ICP-248联合奥布替尼获批III期临床试验

阿斯达克财经
17 Feb

诺诚健华(09969.HK) 公布,国家药品监督管理局药品审评中心已批准在内地进行B细胞淋巴瘤-2 (BCL2)抑制剂ICP-248联合BTK抑制剂奥布替尼治疗一线慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的注册III期临床试验。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-17 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10